Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Normal growth during lamotrigine monotherapy in pediatric epilepsy patients - a prospective evaluation of 103 children and adolescents
Autore:
Ueberall, MA;
Indirizzi:
Univ Erlangen Nurnberg, Hosp Children & Adolescents, Neuropediat Dept, D-91054 Erlangen, Germany Univ Erlangen Nurnberg Erlangen Germany D-91054 -91054 Erlangen, Germany
Titolo Testata:
EPILEPSY RESEARCH
fascicolo: 1, volume: 46, anno: 2001,
pagine: 63 - 67
SICI:
0920-1211(200107)46:1<63:NGDLMI>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
WEIGHT-GAIN; VALPROATE; THERAPY; OBESITY;
Keywords:
antiepileptic drugs; lamotrigine; body weight; body height; body mass index;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
15
Recensione:
Indirizzi per estratti:
Indirizzo: Ueberall, MA Univ Erlangen Nurnberg, Hosp Children & Adolescents, Neuropediat Dept, Loschgestr 15, D-91054 Erlangen, Germany Univ Erlangen Nurnberg Loschgestr 15 Erlangen Germany D-91054
Citazione:
M.A. Ueberall, "Normal growth during lamotrigine monotherapy in pediatric epilepsy patients - a prospective evaluation of 103 children and adolescents", EPILEPSY R, 46(1), 2001, pp. 63-67

Abstract

Physical maturation is one of the essential developmental processes duringchildhood and adolescence, which can be adversely affected by a number of internal and external factors. An important side effect associated with thelong-term use of some antiepileptic drugs is change in body weight, followed by an increased risk for subsequent maturational problems in pediatric epilepsy patients. To evaluate the effect of lamotrigine on body growth in children and adolescents with epilepsy, weight, height and body mass index (BMI) values of 103 pediatric epilepsy patients (m/f ratio: 53/50) treated with lamotrigine monotherapy were prospectively evaluated for a period of 18.7 +/- 11.8 (range 6-71) months. Age at therapy introduction was 6.7 +/- 2.7 (range 1.6-16.3) years and daily lamotrigine dose was 7.4 +/- 2.2 (range 3.5-14.2) mg/kg body weight (BW). Standard deviation scores (S.D.S.) at therapy initiation versus follow-up were height - S.D.S.: 0.07 +/- 0.42 versus0.08 +/- 0.42 (P = n.s.); weight - S.D.S.: - 0.01 +/- 0.44 versus - 0.01 +/- 0.43 (P = n.s.) and BMI - S.D.S.: - 0.24 +/- 0.47 versus - 0.25 +/- 0.37(P = n.s.). Lamotrigine long-term monotherapy was associated with normal body growth in pediatric and adolescent patients with epilepsy, regardless of patient age, gender or duration of therapy. (C) 2001 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 06:19:21